VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations


H. Thomas Watkins

Director and Chairman of the Board

H. Thomas Watkins has served as Chairman of our Board of Directors since March 2014. Mr. Watkins served as the President and Chief Executive Officer of Human Genome Sciences, Inc. and as a member of its Board of Directors from 2004 until August 2012, when Human Genome Sciences, Inc. was acquired by GlaxoSmithKline. Prior to his tenure at Human Genome Sciences, Inc., Mr. Watkins served as President of TAP Pharmaceutical Products, Inc. Mr. Watkins previously held a series of executive positions over the course of nearly twenty years with Abbott Laboratories.

Mr. Watkins also serves on the Board of Directors of Horizon Pharma plc (NASDAQ: HZNP), the Biotechnology Industry Organization ("BIO"), and served as Chair of the BIO Board of Directors from June 2011 until April 2013.

He holds a B.B.A. from the College of William and Mary and an M.B.A from the University of Chicago Graduate School of Business.

Copyright © 2005-2021 Vanda Pharmaceuticals Inc. |